Showing 1 - 10 of 984
Die Innovationskraft von Forschungsleistungen wird oft an Inputs wie Forschungsmitteln oder Outputs wie Patentanmeldungen gemessen. Hier wird ein neuartiger Indikator für pharmazeutische Innovationskraft vorgestellt, der sich auf die weltweiten medizinischen Durchbrüche und die assoziierten...
Persistent link: https://www.econbiz.de/10012663030
show that the industry - whose long - term evolution is driven by innovation, imitation and permanent creation of new …
Persistent link: https://www.econbiz.de/10014048107
We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical andnovel innovation. We do …, reducing their willingness to investin potentially valuable radical innovation …
Persistent link: https://www.econbiz.de/10011928975
Persistent link: https://www.econbiz.de/10010417576
Persistent link: https://www.econbiz.de/10012008954
Persistent link: https://www.econbiz.de/10011754711
This chapter surveys the costs, risks, and challenges encountered in the progressive discovery and development of new pharmaceuticals. The changing methods by which drugs are discovered, the links between companies and academic science, the changing character of public regulation, and the sharp...
Persistent link: https://www.econbiz.de/10014025164
Persistent link: https://www.econbiz.de/10000744309
Persistent link: https://www.econbiz.de/10003921778
-containment measures and innovation issues is performed, then in the second chapter, an empirical study is performed to investigate … price for off-patent markets can contribute in promoting innovation. Finally, in the fourth chapter, the modeling of risk …
Persistent link: https://www.econbiz.de/10011432290